MATTERHORN BIOSCIENCES
Matterhorn is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule. MR1 presents cancer-specific metabolites on the surface of cancer cells that are recognized and killed by T cells bearing a MR1-specific T cell receptor.
MATTERHORN BIOSCIENCES
Industry:
Biopharma Biotechnology Health Care
Founded:
2020-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.matterhornbiosciences.com
Total Employee:
1+
Status:
Active
Total Funding:
30 M USD
Technology used in webpage:
Microsoft Exchange Online Office 365 Mail Squarespace Hosted
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
ADC Biotechnology
ADC BIO is an innovative biotechnology company. Specialising in Antibody Drug Conjugates.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Aurora Cold Plasma Sterilisation
Aurora Cold Plasma Sterilisation provides low temperature plasma sterilator for medical and research purposes.
Biosystems Immunolab
Biosystems International is a biotechnology company engaged in the development of blood-based diagnostics for cancer and chronic diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Invasight
Invasight is a clinical biotech company that focused on revolutionizing cell invasion research.
KronosDNA
KronosDNA Srl is a young biomedical company specialized in the reproductive genetics.
Lifelancer
Lifelancer® is a Freelance & Remote Job Platform in Life Science, IT & Digital Health
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Navid Biotech
Navid Biotech is a biotech firm that focuses on the R&D of simple and visual new nucleic acid detection technology.
Overseed
Overseed is an biotechnology based company which does R&D process on cannabis production for pharmaceutical purposes.
Panorama Medicine
Panorama Medicine is a biotechnology company that focuses on drug discoveries using genomics and computing.
Pathios Therapeutics
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Printivo Group Jsc
3D-bioprinting company in a mission to improve drug-testing and personalized medical therapies through complete printed human organ.
SolasCure
Solascure is a biotechnology company focused on the development of fit for purpose, efficacious wound care products.
Turbine
Turbine's platform understands the inner mechanisms of cancer enabling the discovery of novel targets & precision medicinal therapies.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Vivet Therapeutics
Vivet Therapeutics is a biotechnology company developing gene therapy treatments for orphan diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Versant Ventures
Versant Ventures investment in Venture Round - Matterhorn Biosciences
Official Site Inspections
http://www.matterhornbiosciences.com Semrush global rank: 8.6 M Semrush visits lastest month: 284
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Matterhorn Biosciences"
Matterhorn Biosciences - Crunchbase Company Profile …
Aug 5, 2020 · Matterhorn Biosciences is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule.See details»
Products - Business Intelligence Tools - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Matterhorn Biosciences. Use the PitchBook Platform to explore the full profile.See details»
Matterhorn Biosciences - VentureRadar
Website: https://www.matterhornbiosciences.com Develops MR1 directed cell therapy targeting cancer through a proprietary M-TCR platform, using MR1T cells to selectively kill cancer cells …See details»
Versant Ventures Launches Matterhorn Biosciences
Aug 5, 2020 · BASEL, Switzerland-- ( BUSINESS WIRE )--Versant Ventures today announced the debut of Matterhorn Biosciences AG, a biotechnology company developing T cell receptor …See details»
Matterhorn Biosciences - Products, Competitors, Financials, …
Matterhorn Biosciences is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule. MR1 presents cancer-specific metabolites on the …See details»
Matterhorn Biosciences AG - startup.ch
Matterhorn Biosciences AG: Matterhorn is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule. MR1 presents cancer-specific metabolites on …See details»
Matterhorn Biosciences - Contacts, Employees, Board Members, …
Matterhorn Biosciences is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule.See details»
Matterhorn Biosciences - EU-Startups
Matterhorn Biosciences is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule. MR1 presents cancer-specific metabolites on the surface of cancer cells that are recognized and killed by T …See details»
Versant debuts Matterhorn Biosciences with $30M to create better …
Aug 5, 2020 · Enter Matterhorn Biosciences, Versant Ventures’ latest startup, which is developing a tumor-agnostic T-cell approach. The company emerges from Versant’s Ridgeline discovery …See details»
Versant Ventures commits $30 million to Matterhorn Biosciences
Jun 8, 2020 · Matterhorn Biosciences AG develops T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue …See details»
BioCentury - Off-the-shelf cell therapy pioneers, …
Aug 6, 2020 · Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million …See details»
Matterhorn Biosciences | CipherBio
Explore Matterhorn Biosciences's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Matterhorn Biosciences | Portfolio | Versant Ventures
Matterhorn is a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue …See details»
Working at Matterhorn-Biosciences - Glassdoor
Glassdoor gives you an inside look at what it's like to work at Matterhorn-Biosciences, including salaries, reviews, office photos, and more. This is the Matterhorn-Biosciences company …See details»
Versant Ventures Launches Oncology-Focused Matterhorn …
With a $30 million investment, Versant Ventures launches Matterhorn Biosciences AG, a company developing T cell receptor therapies based on the recent discovery of MR1-restricted …See details»
It’s the climb: Matterhorn debuts to develop T cell receptor …
Aug 5, 2020 · Matterhorn Bioscience AG has launched to develop T-cell receptor therapies based on the power of MR1T cells that have been found to find and kill a range of tumors in various …See details»
Versant Ventures Launches Matterhorn Biosciences
BASEL, Switzerland--(BUSINESS WIRE)--Versant Ventures today announced the debut of Matterhorn Biosciences AG, a biotechnology company developing T cell receptor therapies …See details»
Additional Analysis of MATTERHORN Confirms Global Benefit of …
Jan 24, 2024 · Subgroup analyses of the randomized double-blind phase III MATTERHORN trial continue to show the benefit of adding perioperative durvalumab to standard chemotherapy in …See details»